Testing A New Experimental Drug To Raise Good Cholesterol Level

Testing A New Experimental Drug To Raise Good Cholesterol Level.
An conjectural dose that raises HDL, or "good," cholesterol seems to have passed an endorse hurdle by proving safe in preliminary trials. Although the trial was primarily designed to countenance at safety, researchers scheduled to present the finding Wednesday at the American Heart Association's annual conjunction in Chicago also report that anacetrapib raised HDL cholesterol by 138 percent and shear LDL, HDL's evil twin, almost in half ultima. "We saw very encouraging reductions in clinical events," said Dr Christopher Cannon, conduct author of the study, which also appears in the Nov 18, 2010 pour of the New England Journal of Medicine.

A big study to sustain the results would take four to five years to complete so the drug is still years away from market who is a cardiologist with Brigham and Women's Hospital in Boston. Other experts are intrigued by the findings, but note that the probe is still in very untimely stages kannada. "There are a lot of people in the prevention/lipid field that are simultaneously excited and leery," said Dr Howard Weintraub, clinical concert-master of the Center for the Prevention of Cardiovascular Disease at NYU Langone Medical Center in New York City.

Added Dr John C LaRosa, president of the State University of New York (SUNY) Downstate Medical Center in New York City: "It's very prior but it's momentous because the end drug out of the barrel of this type was not a success. This looks for example a better drug, but it's not definitive by any means. Don't take this to the bank".

LaRosa was referring to torcetrapib, which, such as anacetrapib, belongs to the class of drugs known as cholesterol ester take protein (CETP) inhibitors. A large trial on torcetrapib was killed after investigators found an increased jeopardy of death and other cardiovascular outcomes. "I would be more excited about anacetrapib if I hadn't seen what happened to its cousin torcetrapib. Torcetrapib raised HDL astoundingly but that was down to the ground neutralized by the advance in cardiovascular events".